Free press releases distribution network?

Agency / Source: Plexus Ventures, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement - Pierre Fabre Medicament and Zambon S.p.A. sign commercial agreement in Germany. Plexus Ventures, LLC represented Pierre Fabre in transaction
Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement

 

PRZOOM - /newswire/ - Philadelphia, PA, United States, 2007/02/20 - Pierre Fabre Medicament and Zambon S.p.A. sign commercial agreement in Germany. Plexus Ventures, LLC represented Pierre Fabre in transaction.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Plexus Ventures, LLC, a global pharmaceutical business development firm, announced today the successful execution of an agreement between Pierre Fabre Medicament of France and Zambon S.p.A. of Italy. The deal, signed February 15, 2007, gives Pierre Fabre commercial rights for Zambon’s product portfolio in Germany.

The strategic partnership involves multiple products, including Panotile Cipro (anti-infective), Fluimicil (mucolytic), Monuril and Lorafem (antibiotics). In addition, Pierre Fabre will absorb Zambon’s specialist medical sales force in Germany to provide complete coverage of top physicians and pharmacists thus strengthening Pierre Fabre’s network in the country.

Pierre Fabre Medicament retained Plexus Ventures to assist with the company’s in-licensing and acquisition campaign in Germany. After careful evaluation of the client’s needs as well as a thorough assessment of the market, Plexus Ventures contacted more than 50 companies on behalf of Pierre Fabre and was involved in all aspects of the partnering process, from initial contacts through Due Diligence and final negotiations. The Plexus Ventures team was led by Mr. Pino Modica, Managing Partner, and success of the project was due in large part to the knowledge of the local marketplace brought by Senior Consultants Mr. Klaus Welzel in Frankfurt and Mr. Valerio Zoja in Milan.

"One of the main advantages Plexus Ventures brings to our clients is our strong international presence and extensive contacts within the most important markets in the Pharmaceutical industry," noted Pino Modica. "In this case, we were able to tap into our network of contacts within the industry to bring new opportunities to the table which were not publicly known. We are proud we were able to meet our client’s needs by finding an ideal partner and a deal structure which will benefit both parties in the long run."

Mr. Alain Benoit, Vice President of Corporate Licensing and Acquisitions for Pierre Fabre commented, "We knew that this was a difficult task and we are glad Plexus Ventures was able to meet the challenge and help us to achieve this important strategic objective of consolidating our presence in the German market."

Plexus Ventures (plexusventures.com), founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Plexus Ventures, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mary Alice Strong - PlexusVentures.com 
310-315-7106 mas[.]plexusventures.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Plexus Ventures, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Plexus Ventures, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today